Stockscreener 앱 받기
0.984
0.06%
0.0046
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
What sentiment indicators say about Century Therapeutics Inc. stockJuly 2025 Review & Fast Entry Momentum Alerts - DonanımHaber
Can Century Therapeutics Inc. stock surprise with earnings upsideMarket Weekly Review & Weekly High Momentum Picks - DonanımHaber
Will Century Therapeutics Inc. stock benefit from infrastructure spendingStop Loss & Advanced Technical Signal Analysis - DonanımHaber
Will Century Therapeutics Inc. stock deliver better than expected guidance2025 Geopolitical Influence & Weekly Watchlist for Hot Stocks - DonanımHaber
Can Century Therapeutics Inc. stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - DonanımHaber
Century Therapeutics adds veteran deal-makers to board as pipeline nears clinic - MSN
Why Century Therapeutics Inc. stock is popular among millennialsRisk Management & Target Return Focused Stock Picks - DonanımHaber
There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st
Brent Pfeiffenberger Purchases 52,000 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics CEO Brent Pfeiffenberger Acquires 52,000 Shares - TradingView — Track All Markets
Century Therapeutics (IPSC) CEO and director reports 52,000-share buy - Stock Titan
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic - MyChesCo
Century Therapeutics (NASDAQ:IPSC) Trading Up 2.5% – Still a Buy? - Defense World
Century Therapeutics Earnings Notes - Trefis
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Century Therapeutics, Inc. Updates on Cell Therapy Developments - TradingView — Track All Markets
IPS Cell-Derived Platelets Market to Rise at 9.6% CAGR Through 2025-2031: Industry and Companies Analysis Featuring Megakaryon, Xueji Shengwu, Renerval, Help, Cynata, Fate, and Century TherapeuticsResearchAndMarkets.com - Markets Financial Content
Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors - MSN
Century Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Century Therapeutics director reports zero beneficial share ownership | IPSC SEC FilingForm 3 - Stock Titan
Fed Meeting: Why Century Therapeutics Inc stock attracts global investorsGap Down & Expert Approved Momentum Ideas - moha.gov.vn
Century Therapeutics appoints two new board members By Investing.com - Investing.com Australia
Century Therapeutics Appoints Dr. Han Lee and Dr. Martin Murphy To Board - citybiz
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors - Yahoo Finance
Century Therapeutics appoints two new board members - Investing.com
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - The Manila Times
Century Therapeutics Appoints Dr. Han Lee and Dr. Martin Murphy to Board of Directors - Quiver Quantitative
Century Therapeutics Appoints Accomplished Biotechnology - GlobeNewswire
Officer Russotti Files To Sell 526 Of Century Therapeutics Inc [IPSC] - TradingView — Track All Markets
Century Therapeutics (IPSC) price target decreased by 20.00% to 4.08 - MSN
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN
Will Century Therapeutics Inc. stock outperform international peersMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
What analysts say about APA Corporation stockMarket Sentiment Report & Enter Your Email to Get Stock Alerts - earlytimes.in
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Century Therapeutics 'moving with urgency' to develop drug for Type 1 diabetes - The Business Journals
There is no way Century Therapeutics Inc (IPSC) can keep these numbers up - Setenews
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MSN
IPSC 2026 special meeting to vote on Nasdaq-driven reverse split - Stock Titan
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics Executive Acquires 35,000 Shares - TradingView
Chmn Pfeiffenberger Buys 35,000 ($17.3K) Of Century Therapeutics Inc [IPSC] - TradingView
Officer Cowan Files To Sell 5,462 Of Century Therapeutics Inc [IPSC] - TradingView
Research Analysts Set Expectations for IPSC FY2025 Earnings - Defense World
Century Therapeutics Inc. stock momentum explainedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
What machine learning models say about Century Therapeutics Inc.2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Leerink Partners Reaffirms “Market Perform” Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
Leerink Partnrs Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - Defense World
Take off with Century Therapeutics Inc (IPSC): Get ready for trading - Setenews
What technical signals suggest for Century Therapeutics Inc. stockCPI Data & Accurate Entry and Exit Point Alerts - newser.com
How Century Therapeutics Inc. stock compares to industry benchmarksMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Century Therapeutics Shares Fall After Leerink Partners Downgrade - MarketScreener
0.29%
1.17%
자본화:
|
볼륨(24시간):